April 27, 2023 — A diabetes drug could soon gain FDA approval for weight loss after manufacturer Eli Lilly said Thursday it showed patients lost significant amounts of weight after 72 weeks of treatment. 

The drug, tirzepatide, helped patients in the study lose up to 15.7% of their body weight in a phase III trial. The trial evaluated 938 adults with obesity or overweight and type 2 diabetes, Lilly said in a news release. 

The patients lost an average of 13.4% of their body weight (29.8 pounds) on a 10-milligram dose and 15.7% (34.4 pounds) on a 15-milligram dose compared to placebo.



By prebo

Leave a Reply

Your email address will not be published. Required fields are marked *